Ken Griffin Zentalis Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$4.09 - $16.13 $17,587 - $69,359	4,300 Added 186.96%	6,600 $26,000
Q1 2024 May 15, 2024	SELL	$10.83 - $16.49 $31,407 - $47,820	-2,900 Reduced 55.77%	2,300 $36,000
Q4 2023 Feb 14, 2024	SELL	$9.84 - $20.13 $60,024 - $122,793	-6,100 Reduced 53.98%	5,200 $78,000
Q3 2023 Nov 14, 2023	BUY	$19.63 - $28.29 $200,226 - $288,558	10,200 Added 927.27%	11,300 $226,000
Q2 2023 Aug 14, 2023	BUY	$17.41 - $30.05 $12,187 - $21,035	700 Added 175.0%	1,100 $31,000
Q1 2023 May 15, 2023	SELL	$16.14 - $24.94 $12,912 - $19,952	-800 Reduced 66.67%	400 $6,000
Q4 2022 Feb 14, 2023	BUY	$18.07 - $25.6 $21,684 - $30,720	1,200 New	1,200 $24,000

147

69.9M

61.8K

6.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $156M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.